Biotechnology in Thoughts from the Centre

The FT Global Pharmaceutical and Biotechnology Conference 2019: Forces disrupting the industry

By Karen Taylor, Director, Centre for Health Solutions

Ftg

Last month Deloitte was one of the main sponsors of the 2019 FT Global Pharmaceutical and Biotechnology Conference. This is a key event for the industry, attended by senior industry executives and financial professionals from around the world. The aim of this year’s conference was to focus a critical eye on the forces set to transform the industry in the years ahead. I was privileged to attend the conference and help man our stall where we displayed our research reports, including our report Intelligent biopharma: Powered by AI, which we launched on the first day. We also introduced our new Converge Health platform and the connected patient experience. This week’s blog shares some of the highlights that I took away from the presentations and panel debates that took place on the first day. I will return to day two in a later blog.

Continue reading

Posted on 06/12/2019 | 0 Comments

Intelligent drug discovery: Powered by AI

By Dr Francesca Properzi, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-intelligent-drug-discovery

Next week at the 2019 Global Financial Times Pharmaceutical and Biotechnology conference in London, we will formally launch the second in our series of reports on how artificial intelligence (AI) is driving the digital transformation of biopharma. This second report, Intelligent drug discovery: Powered by AI, explores the rise of ‘disruptive AI for drug discovery’ companies and the challenges and opportunities for biopharma in using AI technologies to help find new, more precise, targeted treatments.1 This blog highlights the key takeaways from our report.

Continue reading

Posted on 08/11/2019 | 0 Comments

Intelligent biopharma: Forging the links across the value chain

By Mark Steedman, PhD, Manager, Centre for Health Solutions

Deloitte-uk-intelligent-biopharma

This week, we have launched the first in a series of reports on artificial intelligence (AI) and its potential impact in driving the digital transformation of biopharma. This overview report, Intelligent biopharma: Forging the links across the value chain, explores the challenges and opportunities in AI adoption and the potential ways that AI might impact the different segments of the biopharma value chain (see Figure 1).1

Continue reading

Posted on 04/10/2019 | 0 Comments

Can objective knowledge on GM foods change public opinion?

By Elliot Birtwhistle, Deloitte Consulting

Salads

Genetic modification (GM) is the process of altering the genes of a living organism. The words invoke images of secret government labs and scientists in white hazmat suits that inject rodents with glowing liquid. The reality is somewhat more nuanced. Genetic modification either inserts a gene, or a small number of genes into a plant or animal – or ‘silences’ an existing gene(s) to produce a genetically modified organism. The applications are widespread and include medicines, consumer products and commercial agriculture. This week’s blog explores some of the issues surrounding GM foods.

Continue reading

Posted on 27/09/2019 | 0 Comments

So, just how attractive are Biosimilars for pharma companies?

By Peter Wallace, Partner in Consulting

Deloitte-uk-biosimilars-for-pharma-companies

Last week’s blog discussed the cost effectiveness of biosimilars and the extent to which they offer value for money for healthcare systems.1 This week’s blog, by Peter Wallace, our lead Partner for digital transformation of Life Sciences and Healthcare, looks at the issue through the lens of the pharma company.

Continue reading

Posted on 20/09/2019 | 0 Comments

The cost-effectiveness of biosimilars: Delivering value for money from pharma spending

By Karen Taylor and Pratik Avhad, Centre for Health Solutions

Deloitte-uk-cost-effectiveness-of-biosimilars

Two months ago, I participated in a Westminster Health Forum panel discussing Biologics and Biosimilars. My remit was to discuss the cost effectiveness of biosimilars and their contribution to value for money in pharma spending. This week’s blog shares the findings from the research we did for the presentation.

Continue reading

Posted on 13/09/2019 | 0 Comments

The journey of my internship: Titanic or Apollo 11?

By Nahiyan Khan, Intern, Monitor Deloitte

Satellite

My journey as an intern started back in December 2018, alone with my laptop and wavering confidence, fuelled by the daunting stories from my peers about the hundreds of internships they had applied to and the succession of rejections they seemed to get like some sort of corporate ‘tinder’. This, coupled with my third year dissertation constantly on my mind, meant that I didn’t have the most motivated mind set. Still, I remember deciding to apply to one last internship before retiring for the day - Monitor Deloitte. This choice came from a mixture of wanting to get an insight into what strategy consulting actually does, and hearing about Deloitte as a great place for a new graduate to start their career. First would come the immersive online assessment, followed by the job simulation and then, if successful, the final assessment (see Figure 1).

Continue reading

Posted on 30/08/2019 | 0 Comments

Forging a new path to commercialization for cell and gene therapies

By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP

Deloitte-uk-green-trees-and-grass

This week’s blog, by Greg Reh from the US firm, first appeared on the US Center for Health Solutions blog site. The blog features Greg’s commentary on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma companies’ current technology systems.

Continue reading

Posted on 16/08/2019 | 0 Comments

Why improving inclusion and diversity in clinical trials should be a research priority

By Karen Taylor, Director, Centre for Health Solutions

Diversity

Several weeks ago I participated in a panel discussion on inclusion and diversity in clinical trials. My research for the event and the discussion that ensued led me to conclude that while there have been some improvements, the pharma industry continues to struggle to recruit sufficient trial participants from important demographic groups, especially women, racial and ethnic minorities, and the elderly. As a result, the outcomes seen in clinical trials are likely to be unrepresentative of the patient outcomes in the real world.

Continue reading

Posted on 08/08/2019 | 0 Comments

Deal breaker? Mitigating cyber risk in life sciences M&A

By Nadeem Mohammed, Deloitte MCS Limited

Lock

Imagine the scene: it’s Friday night, eight senior executives at one of the world’s largest companies are sitting around a private dining table at a swanky city restaurant. They’re there to celebrate the closure of a transaction they’ve been toiling over for the past 12 months. You’re the Deal Lead, and you’ve just taken a congratulatory phone call from the Chief Executive – the Board are delighted with the acquisition, which will now be at the heart of the company’s growth strategy. You’ve given blood, sweat and tears on this – you raise a glass towards the table and take a quiet moment to reflect on what is surely a career defining moment.

Continue reading

Posted on 26/07/2019 | 0 Comments